Columbus VP closes its fourth 150 million fund aimed at developing biotech start-ups
-
- The fund has managed more than 400 million euros in its four accumulated funds, which have resulted in 27 investments and a dozen exits, including Askbio, Viralgen, PTS and Sanifit.
Madrid, Spain, 14 May 2024 - Columbus Venture Partners (VP) has closed on Tuesday its fourth investment fund with a size of 150 million euros for startups in the biotechnology and pharmaceutical sector, while the total amount of its assets under management stands at 400 million. The firm has detailed in a statement that the portfolio of companies selected for this new fund will include between ten and twelve investments, with "a balanced focus on disruptive treatments and industrial development, especially in the drug development process". So far, the fourth fund has already made its first four investments, including US-based Alto Pharmacy and UK-based Curve Therapeutics. In addition, this fund offers the ability to invest from three million euros up to a maximum of twenty million euros over the life cycle of the company. This is because the investment timeframe for selecting portfolio companies is up to three years, with a total period of ten years to close. The Columbus VP team will manage this new fund through the founders and managing partners of the firm, Javier García and Damià Tormo, together with partners Julen Oyarzábal, José Mesa and Robert Armstrong. On the other hand, the entity has recalled that with the three previous vehicles, 27 investments have been made and a dozen exits have already been obtained, including Askbio, Viralgen, PTS and Sanifit. They have also announced that they have founded two new Spanish bioindustrial companies that "will be announced shortly". 
